Global TKI for Chronic Myeloid Leukemia Market Growth 2026-2032
The global TKI for Chronic Myeloid Leukemia market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.
Tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) are a class of targeted therapies designed to inhibit the BCR-ABL fusion protein, which results from the Philadelphia chromosome mutation and drives the uncontrolled growth of leukemic cells. By blocking the signaling pathways associated with this protein, TKIs, such as imatinib, dasatinib, and nilotinib, effectively reduce the proliferation of cancer cells and help restore normal blood cell production.
The market for tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) has experienced significant growth over the past decade, driven by advancements in targeted therapies and increasing awareness of the disease. As the first-line treatment option for CML, TKIs like imatinib have established a solid foundation, leading to the development of second- and third-generation TKIs such as dasatinib and nilotinib, which offer improved efficacy and reduced resistance rates.
Furthermore, the rising incidence of CML and the growing understanding of the disease’s underlying mechanisms have fueled demand for TKIs. Enhanced diagnostic techniques, including genetic testing for the Philadelphia chromosome, allow for earlier detection and more personalized treatment approaches. This trend is supported by ongoing research and clinical trials focused on optimizing TKI regimens and exploring combinations with other therapies, which are likely to contribute to further market expansion.
Additionally, the market landscape is evolving with the entry of biosimilars and generics, which are expected to increase competition and lower treatment costs. As patents for some first-generation TKIs expire, more affordable alternatives are becoming available, making treatment more accessible to a broader patient population. This shift not only enhances patient adherence to therapy but also stimulates healthcare systems to allocate resources effectively. Overall, the TKI market for CML is poised for continued growth, driven by innovation, a better understanding of the disease, and efforts to improve patient outcomes.
LP Information, Inc. (LPI) ' newest research report, the “TKI for Chronic Myeloid Leukemia Industry Forecast” looks at past sales and reviews total world TKI for Chronic Myeloid Leukemia sales in 2025, providing a comprehensive analysis by region and market sector of projected TKI for Chronic Myeloid Leukemia sales for 2026 through 2032. With TKI for Chronic Myeloid Leukemia sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world TKI for Chronic Myeloid Leukemia industry.
This Insight Report provides a comprehensive analysis of the global TKI for Chronic Myeloid Leukemia landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on TKI for Chronic Myeloid Leukemia portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global TKI for Chronic Myeloid Leukemia market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for TKI for Chronic Myeloid Leukemia and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global TKI for Chronic Myeloid Leukemia.
This report presents a comprehensive overview, market shares, and growth opportunities of TKI for Chronic Myeloid Leukemia market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) are a class of targeted therapies designed to inhibit the BCR-ABL fusion protein, which results from the Philadelphia chromosome mutation and drives the uncontrolled growth of leukemic cells. By blocking the signaling pathways associated with this protein, TKIs, such as imatinib, dasatinib, and nilotinib, effectively reduce the proliferation of cancer cells and help restore normal blood cell production.
The market for tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) has experienced significant growth over the past decade, driven by advancements in targeted therapies and increasing awareness of the disease. As the first-line treatment option for CML, TKIs like imatinib have established a solid foundation, leading to the development of second- and third-generation TKIs such as dasatinib and nilotinib, which offer improved efficacy and reduced resistance rates.
Furthermore, the rising incidence of CML and the growing understanding of the disease’s underlying mechanisms have fueled demand for TKIs. Enhanced diagnostic techniques, including genetic testing for the Philadelphia chromosome, allow for earlier detection and more personalized treatment approaches. This trend is supported by ongoing research and clinical trials focused on optimizing TKI regimens and exploring combinations with other therapies, which are likely to contribute to further market expansion.
Additionally, the market landscape is evolving with the entry of biosimilars and generics, which are expected to increase competition and lower treatment costs. As patents for some first-generation TKIs expire, more affordable alternatives are becoming available, making treatment more accessible to a broader patient population. This shift not only enhances patient adherence to therapy but also stimulates healthcare systems to allocate resources effectively. Overall, the TKI market for CML is poised for continued growth, driven by innovation, a better understanding of the disease, and efforts to improve patient outcomes.
LP Information, Inc. (LPI) ' newest research report, the “TKI for Chronic Myeloid Leukemia Industry Forecast” looks at past sales and reviews total world TKI for Chronic Myeloid Leukemia sales in 2025, providing a comprehensive analysis by region and market sector of projected TKI for Chronic Myeloid Leukemia sales for 2026 through 2032. With TKI for Chronic Myeloid Leukemia sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world TKI for Chronic Myeloid Leukemia industry.
This Insight Report provides a comprehensive analysis of the global TKI for Chronic Myeloid Leukemia landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on TKI for Chronic Myeloid Leukemia portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global TKI for Chronic Myeloid Leukemia market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for TKI for Chronic Myeloid Leukemia and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global TKI for Chronic Myeloid Leukemia.
This report presents a comprehensive overview, market shares, and growth opportunities of TKI for Chronic Myeloid Leukemia market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Imatinib
- Nilotinib
- Dasatinib
- Bosutinib
- Flumatinib
- Ponatinib
- Asciminib
- Other
- Hospitals and clinics
- Pharmacies
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Novartis
- Bristol Myers Squibb
- Pfizer
- Hansoh Pharmaceutical
- Takeda Pharmaceuticals
- Sun Pharmaceuticals
- Mylan
- Dr. Reddy's Laboratories
- Teva
- Eugia Pharma
- Hetero
- Sawai Pharmaceutical
- Lupin
- Apotex
- Chia Tai Tianqing Pharmaceutical
- Qilu Pharmaceutical
- CSPC Ouyi Pharmaceutical
- Suzhou Thery Pharmaceutical
- Lunan Pharmaceutical
- What is the 10-year outlook for the global TKI for Chronic Myeloid Leukemia market?
- What factors are driving TKI for Chronic Myeloid Leukemia market growth, globally and by region?
- Which technologies are poised for the fastest growth by market and region?
- How do TKI for Chronic Myeloid Leukemia market opportunities vary by end market size?
- How does TKI for Chronic Myeloid Leukemia break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global TKI for Chronic Myeloid Leukemia Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for TKI for Chronic Myeloid Leukemia by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for TKI for Chronic Myeloid Leukemia by Country/Region, 2021, 2025 & 2032
2.2 TKI for Chronic Myeloid Leukemia Segment by Type
2.2.1 Imatinib
2.2.2 Nilotinib
2.2.3 Dasatinib
2.2.4 Bosutinib
2.2.5 Flumatinib
2.2.6 Ponatinib
2.2.7 Asciminib
2.2.8 Other
2.2.9 TKI for Chronic Myeloid Leukemia Sales by Type
2.2.9.1 Global TKI for Chronic Myeloid Leukemia Sales Market Share by Type (2021-2026)
2.2.9.2 Global TKI for Chronic Myeloid Leukemia Revenue and Market Share by Type (2021-2026)
2.2.9.3 Global TKI for Chronic Myeloid Leukemia Sale Price by Type (2021-2026)
2.3 TKI for Chronic Myeloid Leukemia Segment by Application
2.3.1 Hospitals and clinics
2.3.2 Pharmacies
2.3.3 Others
2.3.4 TKI for Chronic Myeloid Leukemia Sales by Application
2.3.4.1 Global TKI for Chronic Myeloid Leukemia Sale Market Share by Application (2021-2026)
2.3.4.2 Global TKI for Chronic Myeloid Leukemia Revenue and Market Share by Application (2021-2026)
2.3.4.3 Global TKI for Chronic Myeloid Leukemia Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global TKI for Chronic Myeloid Leukemia Breakdown Data by Company
3.1.1 Global TKI for Chronic Myeloid Leukemia Annual Sales by Company (2021-2026)
3.1.2 Global TKI for Chronic Myeloid Leukemia Sales Market Share by Company (2021-2026)
3.2 Global TKI for Chronic Myeloid Leukemia Annual Revenue by Company (2021-2026)
3.2.1 Global TKI for Chronic Myeloid Leukemia Revenue by Company (2021-2026)
3.2.2 Global TKI for Chronic Myeloid Leukemia Revenue Market Share by Company (2021-2026)
3.3 Global TKI for Chronic Myeloid Leukemia Sale Price by Company
3.4 Key Manufacturers TKI for Chronic Myeloid Leukemia Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers TKI for Chronic Myeloid Leukemia Product Location Distribution
3.4.2 Players TKI for Chronic Myeloid Leukemia Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR TKI FOR CHRONIC MYELOID LEUKEMIA BY GEOGRAPHIC REGION
4.1 World Historic TKI for Chronic Myeloid Leukemia Market Size by Geographic Region (2021-2026)
4.1.1 Global TKI for Chronic Myeloid Leukemia Annual Sales by Geographic Region (2021-2026)
4.1.2 Global TKI for Chronic Myeloid Leukemia Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic TKI for Chronic Myeloid Leukemia Market Size by Country/Region (2021-2026)
4.2.1 Global TKI for Chronic Myeloid Leukemia Annual Sales by Country/Region (2021-2026)
4.2.2 Global TKI for Chronic Myeloid Leukemia Annual Revenue by Country/Region (2021-2026)
4.3 Americas TKI for Chronic Myeloid Leukemia Sales Growth
4.4 APAC TKI for Chronic Myeloid Leukemia Sales Growth
4.5 Europe TKI for Chronic Myeloid Leukemia Sales Growth
4.6 Middle East & Africa TKI for Chronic Myeloid Leukemia Sales Growth
5 AMERICAS
5.1 Americas TKI for Chronic Myeloid Leukemia Sales by Country
5.1.1 Americas TKI for Chronic Myeloid Leukemia Sales by Country (2021-2026)
5.1.2 Americas TKI for Chronic Myeloid Leukemia Revenue by Country (2021-2026)
5.2 Americas TKI for Chronic Myeloid Leukemia Sales by Type (2021-2026)
5.3 Americas TKI for Chronic Myeloid Leukemia Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC TKI for Chronic Myeloid Leukemia Sales by Region
6.1.1 APAC TKI for Chronic Myeloid Leukemia Sales by Region (2021-2026)
6.1.2 APAC TKI for Chronic Myeloid Leukemia Revenue by Region (2021-2026)
6.2 APAC TKI for Chronic Myeloid Leukemia Sales by Type (2021-2026)
6.3 APAC TKI for Chronic Myeloid Leukemia Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe TKI for Chronic Myeloid Leukemia by Country
7.1.1 Europe TKI for Chronic Myeloid Leukemia Sales by Country (2021-2026)
7.1.2 Europe TKI for Chronic Myeloid Leukemia Revenue by Country (2021-2026)
7.2 Europe TKI for Chronic Myeloid Leukemia Sales by Type (2021-2026)
7.3 Europe TKI for Chronic Myeloid Leukemia Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa TKI for Chronic Myeloid Leukemia by Country
8.1.1 Middle East & Africa TKI for Chronic Myeloid Leukemia Sales by Country (2021-2026)
8.1.2 Middle East & Africa TKI for Chronic Myeloid Leukemia Revenue by Country (2021-2026)
8.2 Middle East & Africa TKI for Chronic Myeloid Leukemia Sales by Type (2021-2026)
8.3 Middle East & Africa TKI for Chronic Myeloid Leukemia Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of TKI for Chronic Myeloid Leukemia
10.3 Manufacturing Process Analysis of TKI for Chronic Myeloid Leukemia
10.4 Industry Chain Structure of TKI for Chronic Myeloid Leukemia
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 TKI for Chronic Myeloid Leukemia Distributors
11.3 TKI for Chronic Myeloid Leukemia Customer
12 WORLD FORECAST REVIEW FOR TKI FOR CHRONIC MYELOID LEUKEMIA BY GEOGRAPHIC REGION
12.1 Global TKI for Chronic Myeloid Leukemia Market Size Forecast by Region
12.1.1 Global TKI for Chronic Myeloid Leukemia Forecast by Region (2027-2032)
12.1.2 Global TKI for Chronic Myeloid Leukemia Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global TKI for Chronic Myeloid Leukemia Forecast by Type (2027-2032)
12.7 Global TKI for Chronic Myeloid Leukemia Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Novartis
13.1.1 Novartis Company Information
13.1.2 Novartis TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
13.1.3 Novartis TKI for Chronic Myeloid Leukemia Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Novartis Main Business Overview
13.1.5 Novartis Latest Developments
13.2 Bristol Myers Squibb
13.2.1 Bristol Myers Squibb Company Information
13.2.2 Bristol Myers Squibb TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
13.2.3 Bristol Myers Squibb TKI for Chronic Myeloid Leukemia Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Bristol Myers Squibb Main Business Overview
13.2.5 Bristol Myers Squibb Latest Developments
13.3 Pfizer
13.3.1 Pfizer Company Information
13.3.2 Pfizer TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
13.3.3 Pfizer TKI for Chronic Myeloid Leukemia Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Pfizer Main Business Overview
13.3.5 Pfizer Latest Developments
13.4 Hansoh Pharmaceutical
13.4.1 Hansoh Pharmaceutical Company Information
13.4.2 Hansoh Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
13.4.3 Hansoh Pharmaceutical TKI for Chronic Myeloid Leukemia Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Hansoh Pharmaceutical Main Business Overview
13.4.5 Hansoh Pharmaceutical Latest Developments
13.5 Takeda Pharmaceuticals
13.5.1 Takeda Pharmaceuticals Company Information
13.5.2 Takeda Pharmaceuticals TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
13.5.3 Takeda Pharmaceuticals TKI for Chronic Myeloid Leukemia Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Takeda Pharmaceuticals Main Business Overview
13.5.5 Takeda Pharmaceuticals Latest Developments
13.6 Sun Pharmaceuticals
13.6.1 Sun Pharmaceuticals Company Information
13.6.2 Sun Pharmaceuticals TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
13.6.3 Sun Pharmaceuticals TKI for Chronic Myeloid Leukemia Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Sun Pharmaceuticals Main Business Overview
13.6.5 Sun Pharmaceuticals Latest Developments
13.7 Mylan
13.7.1 Mylan Company Information
13.7.2 Mylan TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
13.7.3 Mylan TKI for Chronic Myeloid Leukemia Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Mylan Main Business Overview
13.7.5 Mylan Latest Developments
13.8 Dr. Reddy's Laboratories
13.8.1 Dr. Reddy's Laboratories Company Information
13.8.2 Dr. Reddy's Laboratories TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
13.8.3 Dr. Reddy's Laboratories TKI for Chronic Myeloid Leukemia Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Dr. Reddy's Laboratories Main Business Overview
13.8.5 Dr. Reddy's Laboratories Latest Developments
13.9 Teva
13.9.1 Teva Company Information
13.9.2 Teva TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
13.9.3 Teva TKI for Chronic Myeloid Leukemia Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Teva Main Business Overview
13.9.5 Teva Latest Developments
13.10 Eugia Pharma
13.10.1 Eugia Pharma Company Information
13.10.2 Eugia Pharma TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
13.10.3 Eugia Pharma TKI for Chronic Myeloid Leukemia Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Eugia Pharma Main Business Overview
13.10.5 Eugia Pharma Latest Developments
13.11 Hetero
13.11.1 Hetero Company Information
13.11.2 Hetero TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
13.11.3 Hetero TKI for Chronic Myeloid Leukemia Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Hetero Main Business Overview
13.11.5 Hetero Latest Developments
13.12 Sawai Pharmaceutical
13.12.1 Sawai Pharmaceutical Company Information
13.12.2 Sawai Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
13.12.3 Sawai Pharmaceutical TKI for Chronic Myeloid Leukemia Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Sawai Pharmaceutical Main Business Overview
13.12.5 Sawai Pharmaceutical Latest Developments
13.13 Lupin
13.13.1 Lupin Company Information
13.13.2 Lupin TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
13.13.3 Lupin TKI for Chronic Myeloid Leukemia Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Lupin Main Business Overview
13.13.5 Lupin Latest Developments
13.14 Apotex
13.14.1 Apotex Company Information
13.14.2 Apotex TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
13.14.3 Apotex TKI for Chronic Myeloid Leukemia Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 Apotex Main Business Overview
13.14.5 Apotex Latest Developments
13.15 Chia Tai Tianqing Pharmaceutical
13.15.1 Chia Tai Tianqing Pharmaceutical Company Information
13.15.2 Chia Tai Tianqing Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
13.15.3 Chia Tai Tianqing Pharmaceutical TKI for Chronic Myeloid Leukemia Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 Chia Tai Tianqing Pharmaceutical Main Business Overview
13.15.5 Chia Tai Tianqing Pharmaceutical Latest Developments
13.16 Qilu Pharmaceutical
13.16.1 Qilu Pharmaceutical Company Information
13.16.2 Qilu Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
13.16.3 Qilu Pharmaceutical TKI for Chronic Myeloid Leukemia Sales, Revenue, Price and Gross Margin (2021-2026)
13.16.4 Qilu Pharmaceutical Main Business Overview
13.16.5 Qilu Pharmaceutical Latest Developments
13.17 CSPC Ouyi Pharmaceutical
13.17.1 CSPC Ouyi Pharmaceutical Company Information
13.17.2 CSPC Ouyi Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
13.17.3 CSPC Ouyi Pharmaceutical TKI for Chronic Myeloid Leukemia Sales, Revenue, Price and Gross Margin (2021-2026)
13.17.4 CSPC Ouyi Pharmaceutical Main Business Overview
13.17.5 CSPC Ouyi Pharmaceutical Latest Developments
13.18 Suzhou Thery Pharmaceutical
13.18.1 Suzhou Thery Pharmaceutical Company Information
13.18.2 Suzhou Thery Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
13.18.3 Suzhou Thery Pharmaceutical TKI for Chronic Myeloid Leukemia Sales, Revenue, Price and Gross Margin (2021-2026)
13.18.4 Suzhou Thery Pharmaceutical Main Business Overview
13.18.5 Suzhou Thery Pharmaceutical Latest Developments
13.19 Lunan Pharmaceutical
13.19.1 Lunan Pharmaceutical Company Information
13.19.2 Lunan Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
13.19.3 Lunan Pharmaceutical TKI for Chronic Myeloid Leukemia Sales, Revenue, Price and Gross Margin (2021-2026)
13.19.4 Lunan Pharmaceutical Main Business Overview
13.19.5 Lunan Pharmaceutical Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global TKI for Chronic Myeloid Leukemia Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for TKI for Chronic Myeloid Leukemia by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for TKI for Chronic Myeloid Leukemia by Country/Region, 2021, 2025 & 2032
2.2 TKI for Chronic Myeloid Leukemia Segment by Type
2.2.1 Imatinib
2.2.2 Nilotinib
2.2.3 Dasatinib
2.2.4 Bosutinib
2.2.5 Flumatinib
2.2.6 Ponatinib
2.2.7 Asciminib
2.2.8 Other
2.2.9 TKI for Chronic Myeloid Leukemia Sales by Type
2.2.9.1 Global TKI for Chronic Myeloid Leukemia Sales Market Share by Type (2021-2026)
2.2.9.2 Global TKI for Chronic Myeloid Leukemia Revenue and Market Share by Type (2021-2026)
2.2.9.3 Global TKI for Chronic Myeloid Leukemia Sale Price by Type (2021-2026)
2.3 TKI for Chronic Myeloid Leukemia Segment by Application
2.3.1 Hospitals and clinics
2.3.2 Pharmacies
2.3.3 Others
2.3.4 TKI for Chronic Myeloid Leukemia Sales by Application
2.3.4.1 Global TKI for Chronic Myeloid Leukemia Sale Market Share by Application (2021-2026)
2.3.4.2 Global TKI for Chronic Myeloid Leukemia Revenue and Market Share by Application (2021-2026)
2.3.4.3 Global TKI for Chronic Myeloid Leukemia Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global TKI for Chronic Myeloid Leukemia Breakdown Data by Company
3.1.1 Global TKI for Chronic Myeloid Leukemia Annual Sales by Company (2021-2026)
3.1.2 Global TKI for Chronic Myeloid Leukemia Sales Market Share by Company (2021-2026)
3.2 Global TKI for Chronic Myeloid Leukemia Annual Revenue by Company (2021-2026)
3.2.1 Global TKI for Chronic Myeloid Leukemia Revenue by Company (2021-2026)
3.2.2 Global TKI for Chronic Myeloid Leukemia Revenue Market Share by Company (2021-2026)
3.3 Global TKI for Chronic Myeloid Leukemia Sale Price by Company
3.4 Key Manufacturers TKI for Chronic Myeloid Leukemia Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers TKI for Chronic Myeloid Leukemia Product Location Distribution
3.4.2 Players TKI for Chronic Myeloid Leukemia Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR TKI FOR CHRONIC MYELOID LEUKEMIA BY GEOGRAPHIC REGION
4.1 World Historic TKI for Chronic Myeloid Leukemia Market Size by Geographic Region (2021-2026)
4.1.1 Global TKI for Chronic Myeloid Leukemia Annual Sales by Geographic Region (2021-2026)
4.1.2 Global TKI for Chronic Myeloid Leukemia Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic TKI for Chronic Myeloid Leukemia Market Size by Country/Region (2021-2026)
4.2.1 Global TKI for Chronic Myeloid Leukemia Annual Sales by Country/Region (2021-2026)
4.2.2 Global TKI for Chronic Myeloid Leukemia Annual Revenue by Country/Region (2021-2026)
4.3 Americas TKI for Chronic Myeloid Leukemia Sales Growth
4.4 APAC TKI for Chronic Myeloid Leukemia Sales Growth
4.5 Europe TKI for Chronic Myeloid Leukemia Sales Growth
4.6 Middle East & Africa TKI for Chronic Myeloid Leukemia Sales Growth
5 AMERICAS
5.1 Americas TKI for Chronic Myeloid Leukemia Sales by Country
5.1.1 Americas TKI for Chronic Myeloid Leukemia Sales by Country (2021-2026)
5.1.2 Americas TKI for Chronic Myeloid Leukemia Revenue by Country (2021-2026)
5.2 Americas TKI for Chronic Myeloid Leukemia Sales by Type (2021-2026)
5.3 Americas TKI for Chronic Myeloid Leukemia Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC TKI for Chronic Myeloid Leukemia Sales by Region
6.1.1 APAC TKI for Chronic Myeloid Leukemia Sales by Region (2021-2026)
6.1.2 APAC TKI for Chronic Myeloid Leukemia Revenue by Region (2021-2026)
6.2 APAC TKI for Chronic Myeloid Leukemia Sales by Type (2021-2026)
6.3 APAC TKI for Chronic Myeloid Leukemia Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe TKI for Chronic Myeloid Leukemia by Country
7.1.1 Europe TKI for Chronic Myeloid Leukemia Sales by Country (2021-2026)
7.1.2 Europe TKI for Chronic Myeloid Leukemia Revenue by Country (2021-2026)
7.2 Europe TKI for Chronic Myeloid Leukemia Sales by Type (2021-2026)
7.3 Europe TKI for Chronic Myeloid Leukemia Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa TKI for Chronic Myeloid Leukemia by Country
8.1.1 Middle East & Africa TKI for Chronic Myeloid Leukemia Sales by Country (2021-2026)
8.1.2 Middle East & Africa TKI for Chronic Myeloid Leukemia Revenue by Country (2021-2026)
8.2 Middle East & Africa TKI for Chronic Myeloid Leukemia Sales by Type (2021-2026)
8.3 Middle East & Africa TKI for Chronic Myeloid Leukemia Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of TKI for Chronic Myeloid Leukemia
10.3 Manufacturing Process Analysis of TKI for Chronic Myeloid Leukemia
10.4 Industry Chain Structure of TKI for Chronic Myeloid Leukemia
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 TKI for Chronic Myeloid Leukemia Distributors
11.3 TKI for Chronic Myeloid Leukemia Customer
12 WORLD FORECAST REVIEW FOR TKI FOR CHRONIC MYELOID LEUKEMIA BY GEOGRAPHIC REGION
12.1 Global TKI for Chronic Myeloid Leukemia Market Size Forecast by Region
12.1.1 Global TKI for Chronic Myeloid Leukemia Forecast by Region (2027-2032)
12.1.2 Global TKI for Chronic Myeloid Leukemia Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global TKI for Chronic Myeloid Leukemia Forecast by Type (2027-2032)
12.7 Global TKI for Chronic Myeloid Leukemia Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Novartis
13.1.1 Novartis Company Information
13.1.2 Novartis TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
13.1.3 Novartis TKI for Chronic Myeloid Leukemia Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Novartis Main Business Overview
13.1.5 Novartis Latest Developments
13.2 Bristol Myers Squibb
13.2.1 Bristol Myers Squibb Company Information
13.2.2 Bristol Myers Squibb TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
13.2.3 Bristol Myers Squibb TKI for Chronic Myeloid Leukemia Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Bristol Myers Squibb Main Business Overview
13.2.5 Bristol Myers Squibb Latest Developments
13.3 Pfizer
13.3.1 Pfizer Company Information
13.3.2 Pfizer TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
13.3.3 Pfizer TKI for Chronic Myeloid Leukemia Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Pfizer Main Business Overview
13.3.5 Pfizer Latest Developments
13.4 Hansoh Pharmaceutical
13.4.1 Hansoh Pharmaceutical Company Information
13.4.2 Hansoh Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
13.4.3 Hansoh Pharmaceutical TKI for Chronic Myeloid Leukemia Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Hansoh Pharmaceutical Main Business Overview
13.4.5 Hansoh Pharmaceutical Latest Developments
13.5 Takeda Pharmaceuticals
13.5.1 Takeda Pharmaceuticals Company Information
13.5.2 Takeda Pharmaceuticals TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
13.5.3 Takeda Pharmaceuticals TKI for Chronic Myeloid Leukemia Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Takeda Pharmaceuticals Main Business Overview
13.5.5 Takeda Pharmaceuticals Latest Developments
13.6 Sun Pharmaceuticals
13.6.1 Sun Pharmaceuticals Company Information
13.6.2 Sun Pharmaceuticals TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
13.6.3 Sun Pharmaceuticals TKI for Chronic Myeloid Leukemia Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Sun Pharmaceuticals Main Business Overview
13.6.5 Sun Pharmaceuticals Latest Developments
13.7 Mylan
13.7.1 Mylan Company Information
13.7.2 Mylan TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
13.7.3 Mylan TKI for Chronic Myeloid Leukemia Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Mylan Main Business Overview
13.7.5 Mylan Latest Developments
13.8 Dr. Reddy's Laboratories
13.8.1 Dr. Reddy's Laboratories Company Information
13.8.2 Dr. Reddy's Laboratories TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
13.8.3 Dr. Reddy's Laboratories TKI for Chronic Myeloid Leukemia Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Dr. Reddy's Laboratories Main Business Overview
13.8.5 Dr. Reddy's Laboratories Latest Developments
13.9 Teva
13.9.1 Teva Company Information
13.9.2 Teva TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
13.9.3 Teva TKI for Chronic Myeloid Leukemia Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Teva Main Business Overview
13.9.5 Teva Latest Developments
13.10 Eugia Pharma
13.10.1 Eugia Pharma Company Information
13.10.2 Eugia Pharma TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
13.10.3 Eugia Pharma TKI for Chronic Myeloid Leukemia Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Eugia Pharma Main Business Overview
13.10.5 Eugia Pharma Latest Developments
13.11 Hetero
13.11.1 Hetero Company Information
13.11.2 Hetero TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
13.11.3 Hetero TKI for Chronic Myeloid Leukemia Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Hetero Main Business Overview
13.11.5 Hetero Latest Developments
13.12 Sawai Pharmaceutical
13.12.1 Sawai Pharmaceutical Company Information
13.12.2 Sawai Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
13.12.3 Sawai Pharmaceutical TKI for Chronic Myeloid Leukemia Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Sawai Pharmaceutical Main Business Overview
13.12.5 Sawai Pharmaceutical Latest Developments
13.13 Lupin
13.13.1 Lupin Company Information
13.13.2 Lupin TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
13.13.3 Lupin TKI for Chronic Myeloid Leukemia Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Lupin Main Business Overview
13.13.5 Lupin Latest Developments
13.14 Apotex
13.14.1 Apotex Company Information
13.14.2 Apotex TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
13.14.3 Apotex TKI for Chronic Myeloid Leukemia Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 Apotex Main Business Overview
13.14.5 Apotex Latest Developments
13.15 Chia Tai Tianqing Pharmaceutical
13.15.1 Chia Tai Tianqing Pharmaceutical Company Information
13.15.2 Chia Tai Tianqing Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
13.15.3 Chia Tai Tianqing Pharmaceutical TKI for Chronic Myeloid Leukemia Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 Chia Tai Tianqing Pharmaceutical Main Business Overview
13.15.5 Chia Tai Tianqing Pharmaceutical Latest Developments
13.16 Qilu Pharmaceutical
13.16.1 Qilu Pharmaceutical Company Information
13.16.2 Qilu Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
13.16.3 Qilu Pharmaceutical TKI for Chronic Myeloid Leukemia Sales, Revenue, Price and Gross Margin (2021-2026)
13.16.4 Qilu Pharmaceutical Main Business Overview
13.16.5 Qilu Pharmaceutical Latest Developments
13.17 CSPC Ouyi Pharmaceutical
13.17.1 CSPC Ouyi Pharmaceutical Company Information
13.17.2 CSPC Ouyi Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
13.17.3 CSPC Ouyi Pharmaceutical TKI for Chronic Myeloid Leukemia Sales, Revenue, Price and Gross Margin (2021-2026)
13.17.4 CSPC Ouyi Pharmaceutical Main Business Overview
13.17.5 CSPC Ouyi Pharmaceutical Latest Developments
13.18 Suzhou Thery Pharmaceutical
13.18.1 Suzhou Thery Pharmaceutical Company Information
13.18.2 Suzhou Thery Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
13.18.3 Suzhou Thery Pharmaceutical TKI for Chronic Myeloid Leukemia Sales, Revenue, Price and Gross Margin (2021-2026)
13.18.4 Suzhou Thery Pharmaceutical Main Business Overview
13.18.5 Suzhou Thery Pharmaceutical Latest Developments
13.19 Lunan Pharmaceutical
13.19.1 Lunan Pharmaceutical Company Information
13.19.2 Lunan Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
13.19.3 Lunan Pharmaceutical TKI for Chronic Myeloid Leukemia Sales, Revenue, Price and Gross Margin (2021-2026)
13.19.4 Lunan Pharmaceutical Main Business Overview
13.19.5 Lunan Pharmaceutical Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. TKI for Chronic Myeloid Leukemia Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. TKI for Chronic Myeloid Leukemia Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Imatinib
Table 4. Major Players of Nilotinib
Table 5. Major Players of Dasatinib
Table 6. Major Players of Bosutinib
Table 7. Major Players of Flumatinib
Table 8. Major Players of Ponatinib
Table 9. Major Players of Asciminib
Table 10. Major Players of Other
Table 11. Global TKI for Chronic Myeloid Leukemia Sales by Type (2021-2026) & (K Units)
Table 12. Global TKI for Chronic Myeloid Leukemia Sales Market Share by Type (2021-2026)
Table 13. Global TKI for Chronic Myeloid Leukemia Revenue by Type (2021-2026) & ($ million)
Table 14. Global TKI for Chronic Myeloid Leukemia Revenue Market Share by Type (2021-2026)
Table 15. Global TKI for Chronic Myeloid Leukemia Sale Price by Type (2021-2026) & (US$/Unit)
Table 16. Global TKI for Chronic Myeloid Leukemia Sale by Application (2021-2026) & (K Units)
Table 17. Global TKI for Chronic Myeloid Leukemia Sale Market Share by Application (2021-2026)
Table 18. Global TKI for Chronic Myeloid Leukemia Revenue by Application (2021-2026) & ($ million)
Table 19. Global TKI for Chronic Myeloid Leukemia Revenue Market Share by Application (2021-2026)
Table 20. Global TKI for Chronic Myeloid Leukemia Sale Price by Application (2021-2026) & (US$/Unit)
Table 21. Global TKI for Chronic Myeloid Leukemia Sales by Company (2021-2026) & (K Units)
Table 22. Global TKI for Chronic Myeloid Leukemia Sales Market Share by Company (2021-2026)
Table 23. Global TKI for Chronic Myeloid Leukemia Revenue by Company (2021-2026) & ($ millions)
Table 24. Global TKI for Chronic Myeloid Leukemia Revenue Market Share by Company (2021-2026)
Table 25. Global TKI for Chronic Myeloid Leukemia Sale Price by Company (2021-2026) & (US$/Unit)
Table 26. Key Manufacturers TKI for Chronic Myeloid Leukemia Producing Area Distribution and Sales Area
Table 27. Players TKI for Chronic Myeloid Leukemia Products Offered
Table 28. TKI for Chronic Myeloid Leukemia Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 29. New Products and Potential Entrants
Table 30. Market M&A Activity & Strategy
Table 31. Global TKI for Chronic Myeloid Leukemia Sales by Geographic Region (2021-2026) & (K Units)
Table 32. Global TKI for Chronic Myeloid Leukemia Sales Market Share Geographic Region (2021-2026)
Table 33. Global TKI for Chronic Myeloid Leukemia Revenue by Geographic Region (2021-2026) & ($ millions)
Table 34. Global TKI for Chronic Myeloid Leukemia Revenue Market Share by Geographic Region (2021-2026)
Table 35. Global TKI for Chronic Myeloid Leukemia Sales by Country/Region (2021-2026) & (K Units)
Table 36. Global TKI for Chronic Myeloid Leukemia Sales Market Share by Country/Region (2021-2026)
Table 37. Global TKI for Chronic Myeloid Leukemia Revenue by Country/Region (2021-2026) & ($ millions)
Table 38. Global TKI for Chronic Myeloid Leukemia Revenue Market Share by Country/Region (2021-2026)
Table 39. Americas TKI for Chronic Myeloid Leukemia Sales by Country (2021-2026) & (K Units)
Table 40. Americas TKI for Chronic Myeloid Leukemia Sales Market Share by Country (2021-2026)
Table 41. Americas TKI for Chronic Myeloid Leukemia Revenue by Country (2021-2026) & ($ millions)
Table 42. Americas TKI for Chronic Myeloid Leukemia Sales by Type (2021-2026) & (K Units)
Table 43. Americas TKI for Chronic Myeloid Leukemia Sales by Application (2021-2026) & (K Units)
Table 44. APAC TKI for Chronic Myeloid Leukemia Sales by Region (2021-2026) & (K Units)
Table 45. APAC TKI for Chronic Myeloid Leukemia Sales Market Share by Region (2021-2026)
Table 46. APAC TKI for Chronic Myeloid Leukemia Revenue by Region (2021-2026) & ($ millions)
Table 47. APAC TKI for Chronic Myeloid Leukemia Sales by Type (2021-2026) & (K Units)
Table 48. APAC TKI for Chronic Myeloid Leukemia Sales by Application (2021-2026) & (K Units)
Table 49. Europe TKI for Chronic Myeloid Leukemia Sales by Country (2021-2026) & (K Units)
Table 50. Europe TKI for Chronic Myeloid Leukemia Revenue by Country (2021-2026) & ($ millions)
Table 51. Europe TKI for Chronic Myeloid Leukemia Sales by Type (2021-2026) & (K Units)
Table 52. Europe TKI for Chronic Myeloid Leukemia Sales by Application (2021-2026) & (K Units)
Table 53. Middle East & Africa TKI for Chronic Myeloid Leukemia Sales by Country (2021-2026) & (K Units)
Table 54. Middle East & Africa TKI for Chronic Myeloid Leukemia Revenue Market Share by Country (2021-2026)
Table 55. Middle East & Africa TKI for Chronic Myeloid Leukemia Sales by Type (2021-2026) & (K Units)
Table 56. Middle East & Africa TKI for Chronic Myeloid Leukemia Sales by Application (2021-2026) & (K Units)
Table 57. Key Market Drivers & Growth Opportunities of TKI for Chronic Myeloid Leukemia
Table 58. Key Market Challenges & Risks of TKI for Chronic Myeloid Leukemia
Table 59. Key Industry Trends of TKI for Chronic Myeloid Leukemia
Table 60. TKI for Chronic Myeloid Leukemia Raw Material
Table 61. Key Suppliers of Raw Materials
Table 62. TKI for Chronic Myeloid Leukemia Distributors List
Table 63. TKI for Chronic Myeloid Leukemia Customer List
Table 64. Global TKI for Chronic Myeloid Leukemia Sales Forecast by Region (2027-2032) & (K Units)
Table 65. Global TKI for Chronic Myeloid Leukemia Revenue Forecast by Region (2027-2032) & ($ millions)
Table 66. Americas TKI for Chronic Myeloid Leukemia Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Americas TKI for Chronic Myeloid Leukemia Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. APAC TKI for Chronic Myeloid Leukemia Sales Forecast by Region (2027-2032) & (K Units)
Table 69. APAC TKI for Chronic Myeloid Leukemia Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 70. Europe TKI for Chronic Myeloid Leukemia Sales Forecast by Country (2027-2032) & (K Units)
Table 71. Europe TKI for Chronic Myeloid Leukemia Revenue Forecast by Country (2027-2032) & ($ millions)
Table 72. Middle East & Africa TKI for Chronic Myeloid Leukemia Sales Forecast by Country (2027-2032) & (K Units)
Table 73. Middle East & Africa TKI for Chronic Myeloid Leukemia Revenue Forecast by Country (2027-2032) & ($ millions)
Table 74. Global TKI for Chronic Myeloid Leukemia Sales Forecast by Type (2027-2032) & (K Units)
Table 75. Global TKI for Chronic Myeloid Leukemia Revenue Forecast by Type (2027-2032) & ($ millions)
Table 76. Global TKI for Chronic Myeloid Leukemia Sales Forecast by Application (2027-2032) & (K Units)
Table 77. Global TKI for Chronic Myeloid Leukemia Revenue Forecast by Application (2027-2032) & ($ millions)
Table 78. Novartis Basic Information, TKI for Chronic Myeloid Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 79. Novartis TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
Table 80. Novartis TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 81. Novartis Main Business
Table 82. Novartis Latest Developments
Table 83. Bristol Myers Squibb Basic Information, TKI for Chronic Myeloid Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 84. Bristol Myers Squibb TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
Table 85. Bristol Myers Squibb TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 86. Bristol Myers Squibb Main Business
Table 87. Bristol Myers Squibb Latest Developments
Table 88. Pfizer Basic Information, TKI for Chronic Myeloid Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 89. Pfizer TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
Table 90. Pfizer TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 91. Pfizer Main Business
Table 92. Pfizer Latest Developments
Table 93. Hansoh Pharmaceutical Basic Information, TKI for Chronic Myeloid Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 94. Hansoh Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
Table 95. Hansoh Pharmaceutical TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 96. Hansoh Pharmaceutical Main Business
Table 97. Hansoh Pharmaceutical Latest Developments
Table 98. Takeda Pharmaceuticals Basic Information, TKI for Chronic Myeloid Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 99. Takeda Pharmaceuticals TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
Table 100. Takeda Pharmaceuticals TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 101. Takeda Pharmaceuticals Main Business
Table 102. Takeda Pharmaceuticals Latest Developments
Table 103. Sun Pharmaceuticals Basic Information, TKI for Chronic Myeloid Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 104. Sun Pharmaceuticals TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
Table 105. Sun Pharmaceuticals TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 106. Sun Pharmaceuticals Main Business
Table 107. Sun Pharmaceuticals Latest Developments
Table 108. Mylan Basic Information, TKI for Chronic Myeloid Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 109. Mylan TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
Table 110. Mylan TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 111. Mylan Main Business
Table 112. Mylan Latest Developments
Table 113. Dr. Reddy's Laboratories Basic Information, TKI for Chronic Myeloid Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 114. Dr. Reddy's Laboratories TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
Table 115. Dr. Reddy's Laboratories TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 116. Dr. Reddy's Laboratories Main Business
Table 117. Dr. Reddy's Laboratories Latest Developments
Table 118. Teva Basic Information, TKI for Chronic Myeloid Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 119. Teva TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
Table 120. Teva TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 121. Teva Main Business
Table 122. Teva Latest Developments
Table 123. Eugia Pharma Basic Information, TKI for Chronic Myeloid Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 124. Eugia Pharma TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
Table 125. Eugia Pharma TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 126. Eugia Pharma Main Business
Table 127. Eugia Pharma Latest Developments
Table 128. Hetero Basic Information, TKI for Chronic Myeloid Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 129. Hetero TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
Table 130. Hetero TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 131. Hetero Main Business
Table 132. Hetero Latest Developments
Table 133. Sawai Pharmaceutical Basic Information, TKI for Chronic Myeloid Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 134. Sawai Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
Table 135. Sawai Pharmaceutical TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 136. Sawai Pharmaceutical Main Business
Table 137. Sawai Pharmaceutical Latest Developments
Table 138. Lupin Basic Information, TKI for Chronic Myeloid Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 139. Lupin TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
Table 140. Lupin TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 141. Lupin Main Business
Table 142. Lupin Latest Developments
Table 143. Apotex Basic Information, TKI for Chronic Myeloid Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 144. Apotex TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
Table 145. Apotex TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 146. Apotex Main Business
Table 147. Apotex Latest Developments
Table 148. Chia Tai Tianqing Pharmaceutical Basic Information, TKI for Chronic Myeloid Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 149. Chia Tai Tianqing Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
Table 150. Chia Tai Tianqing Pharmaceutical TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 151. Chia Tai Tianqing Pharmaceutical Main Business
Table 152. Chia Tai Tianqing Pharmaceutical Latest Developments
Table 153. Qilu Pharmaceutical Basic Information, TKI for Chronic Myeloid Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 154. Qilu Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
Table 155. Qilu Pharmaceutical TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 156. Qilu Pharmaceutical Main Business
Table 157. Qilu Pharmaceutical Latest Developments
Table 158. CSPC Ouyi Pharmaceutical Basic Information, TKI for Chronic Myeloid Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 159. CSPC Ouyi Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
Table 160. CSPC Ouyi Pharmaceutical TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 161. CSPC Ouyi Pharmaceutical Main Business
Table 162. CSPC Ouyi Pharmaceutical Latest Developments
Table 163. Suzhou Thery Pharmaceutical Basic Information, TKI for Chronic Myeloid Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 164. Suzhou Thery Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
Table 165. Suzhou Thery Pharmaceutical TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 166. Suzhou Thery Pharmaceutical Main Business
Table 167. Suzhou Thery Pharmaceutical Latest Developments
Table 168. Lunan Pharmaceutical Basic Information, TKI for Chronic Myeloid Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 169. Lunan Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
Table 170. Lunan Pharmaceutical TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 171. Lunan Pharmaceutical Main Business
Table 172. Lunan Pharmaceutical Latest Developments
Table 1. TKI for Chronic Myeloid Leukemia Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. TKI for Chronic Myeloid Leukemia Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Imatinib
Table 4. Major Players of Nilotinib
Table 5. Major Players of Dasatinib
Table 6. Major Players of Bosutinib
Table 7. Major Players of Flumatinib
Table 8. Major Players of Ponatinib
Table 9. Major Players of Asciminib
Table 10. Major Players of Other
Table 11. Global TKI for Chronic Myeloid Leukemia Sales by Type (2021-2026) & (K Units)
Table 12. Global TKI for Chronic Myeloid Leukemia Sales Market Share by Type (2021-2026)
Table 13. Global TKI for Chronic Myeloid Leukemia Revenue by Type (2021-2026) & ($ million)
Table 14. Global TKI for Chronic Myeloid Leukemia Revenue Market Share by Type (2021-2026)
Table 15. Global TKI for Chronic Myeloid Leukemia Sale Price by Type (2021-2026) & (US$/Unit)
Table 16. Global TKI for Chronic Myeloid Leukemia Sale by Application (2021-2026) & (K Units)
Table 17. Global TKI for Chronic Myeloid Leukemia Sale Market Share by Application (2021-2026)
Table 18. Global TKI for Chronic Myeloid Leukemia Revenue by Application (2021-2026) & ($ million)
Table 19. Global TKI for Chronic Myeloid Leukemia Revenue Market Share by Application (2021-2026)
Table 20. Global TKI for Chronic Myeloid Leukemia Sale Price by Application (2021-2026) & (US$/Unit)
Table 21. Global TKI for Chronic Myeloid Leukemia Sales by Company (2021-2026) & (K Units)
Table 22. Global TKI for Chronic Myeloid Leukemia Sales Market Share by Company (2021-2026)
Table 23. Global TKI for Chronic Myeloid Leukemia Revenue by Company (2021-2026) & ($ millions)
Table 24. Global TKI for Chronic Myeloid Leukemia Revenue Market Share by Company (2021-2026)
Table 25. Global TKI for Chronic Myeloid Leukemia Sale Price by Company (2021-2026) & (US$/Unit)
Table 26. Key Manufacturers TKI for Chronic Myeloid Leukemia Producing Area Distribution and Sales Area
Table 27. Players TKI for Chronic Myeloid Leukemia Products Offered
Table 28. TKI for Chronic Myeloid Leukemia Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 29. New Products and Potential Entrants
Table 30. Market M&A Activity & Strategy
Table 31. Global TKI for Chronic Myeloid Leukemia Sales by Geographic Region (2021-2026) & (K Units)
Table 32. Global TKI for Chronic Myeloid Leukemia Sales Market Share Geographic Region (2021-2026)
Table 33. Global TKI for Chronic Myeloid Leukemia Revenue by Geographic Region (2021-2026) & ($ millions)
Table 34. Global TKI for Chronic Myeloid Leukemia Revenue Market Share by Geographic Region (2021-2026)
Table 35. Global TKI for Chronic Myeloid Leukemia Sales by Country/Region (2021-2026) & (K Units)
Table 36. Global TKI for Chronic Myeloid Leukemia Sales Market Share by Country/Region (2021-2026)
Table 37. Global TKI for Chronic Myeloid Leukemia Revenue by Country/Region (2021-2026) & ($ millions)
Table 38. Global TKI for Chronic Myeloid Leukemia Revenue Market Share by Country/Region (2021-2026)
Table 39. Americas TKI for Chronic Myeloid Leukemia Sales by Country (2021-2026) & (K Units)
Table 40. Americas TKI for Chronic Myeloid Leukemia Sales Market Share by Country (2021-2026)
Table 41. Americas TKI for Chronic Myeloid Leukemia Revenue by Country (2021-2026) & ($ millions)
Table 42. Americas TKI for Chronic Myeloid Leukemia Sales by Type (2021-2026) & (K Units)
Table 43. Americas TKI for Chronic Myeloid Leukemia Sales by Application (2021-2026) & (K Units)
Table 44. APAC TKI for Chronic Myeloid Leukemia Sales by Region (2021-2026) & (K Units)
Table 45. APAC TKI for Chronic Myeloid Leukemia Sales Market Share by Region (2021-2026)
Table 46. APAC TKI for Chronic Myeloid Leukemia Revenue by Region (2021-2026) & ($ millions)
Table 47. APAC TKI for Chronic Myeloid Leukemia Sales by Type (2021-2026) & (K Units)
Table 48. APAC TKI for Chronic Myeloid Leukemia Sales by Application (2021-2026) & (K Units)
Table 49. Europe TKI for Chronic Myeloid Leukemia Sales by Country (2021-2026) & (K Units)
Table 50. Europe TKI for Chronic Myeloid Leukemia Revenue by Country (2021-2026) & ($ millions)
Table 51. Europe TKI for Chronic Myeloid Leukemia Sales by Type (2021-2026) & (K Units)
Table 52. Europe TKI for Chronic Myeloid Leukemia Sales by Application (2021-2026) & (K Units)
Table 53. Middle East & Africa TKI for Chronic Myeloid Leukemia Sales by Country (2021-2026) & (K Units)
Table 54. Middle East & Africa TKI for Chronic Myeloid Leukemia Revenue Market Share by Country (2021-2026)
Table 55. Middle East & Africa TKI for Chronic Myeloid Leukemia Sales by Type (2021-2026) & (K Units)
Table 56. Middle East & Africa TKI for Chronic Myeloid Leukemia Sales by Application (2021-2026) & (K Units)
Table 57. Key Market Drivers & Growth Opportunities of TKI for Chronic Myeloid Leukemia
Table 58. Key Market Challenges & Risks of TKI for Chronic Myeloid Leukemia
Table 59. Key Industry Trends of TKI for Chronic Myeloid Leukemia
Table 60. TKI for Chronic Myeloid Leukemia Raw Material
Table 61. Key Suppliers of Raw Materials
Table 62. TKI for Chronic Myeloid Leukemia Distributors List
Table 63. TKI for Chronic Myeloid Leukemia Customer List
Table 64. Global TKI for Chronic Myeloid Leukemia Sales Forecast by Region (2027-2032) & (K Units)
Table 65. Global TKI for Chronic Myeloid Leukemia Revenue Forecast by Region (2027-2032) & ($ millions)
Table 66. Americas TKI for Chronic Myeloid Leukemia Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Americas TKI for Chronic Myeloid Leukemia Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. APAC TKI for Chronic Myeloid Leukemia Sales Forecast by Region (2027-2032) & (K Units)
Table 69. APAC TKI for Chronic Myeloid Leukemia Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 70. Europe TKI for Chronic Myeloid Leukemia Sales Forecast by Country (2027-2032) & (K Units)
Table 71. Europe TKI for Chronic Myeloid Leukemia Revenue Forecast by Country (2027-2032) & ($ millions)
Table 72. Middle East & Africa TKI for Chronic Myeloid Leukemia Sales Forecast by Country (2027-2032) & (K Units)
Table 73. Middle East & Africa TKI for Chronic Myeloid Leukemia Revenue Forecast by Country (2027-2032) & ($ millions)
Table 74. Global TKI for Chronic Myeloid Leukemia Sales Forecast by Type (2027-2032) & (K Units)
Table 75. Global TKI for Chronic Myeloid Leukemia Revenue Forecast by Type (2027-2032) & ($ millions)
Table 76. Global TKI for Chronic Myeloid Leukemia Sales Forecast by Application (2027-2032) & (K Units)
Table 77. Global TKI for Chronic Myeloid Leukemia Revenue Forecast by Application (2027-2032) & ($ millions)
Table 78. Novartis Basic Information, TKI for Chronic Myeloid Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 79. Novartis TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
Table 80. Novartis TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 81. Novartis Main Business
Table 82. Novartis Latest Developments
Table 83. Bristol Myers Squibb Basic Information, TKI for Chronic Myeloid Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 84. Bristol Myers Squibb TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
Table 85. Bristol Myers Squibb TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 86. Bristol Myers Squibb Main Business
Table 87. Bristol Myers Squibb Latest Developments
Table 88. Pfizer Basic Information, TKI for Chronic Myeloid Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 89. Pfizer TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
Table 90. Pfizer TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 91. Pfizer Main Business
Table 92. Pfizer Latest Developments
Table 93. Hansoh Pharmaceutical Basic Information, TKI for Chronic Myeloid Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 94. Hansoh Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
Table 95. Hansoh Pharmaceutical TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 96. Hansoh Pharmaceutical Main Business
Table 97. Hansoh Pharmaceutical Latest Developments
Table 98. Takeda Pharmaceuticals Basic Information, TKI for Chronic Myeloid Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 99. Takeda Pharmaceuticals TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
Table 100. Takeda Pharmaceuticals TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 101. Takeda Pharmaceuticals Main Business
Table 102. Takeda Pharmaceuticals Latest Developments
Table 103. Sun Pharmaceuticals Basic Information, TKI for Chronic Myeloid Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 104. Sun Pharmaceuticals TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
Table 105. Sun Pharmaceuticals TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 106. Sun Pharmaceuticals Main Business
Table 107. Sun Pharmaceuticals Latest Developments
Table 108. Mylan Basic Information, TKI for Chronic Myeloid Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 109. Mylan TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
Table 110. Mylan TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 111. Mylan Main Business
Table 112. Mylan Latest Developments
Table 113. Dr. Reddy's Laboratories Basic Information, TKI for Chronic Myeloid Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 114. Dr. Reddy's Laboratories TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
Table 115. Dr. Reddy's Laboratories TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 116. Dr. Reddy's Laboratories Main Business
Table 117. Dr. Reddy's Laboratories Latest Developments
Table 118. Teva Basic Information, TKI for Chronic Myeloid Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 119. Teva TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
Table 120. Teva TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 121. Teva Main Business
Table 122. Teva Latest Developments
Table 123. Eugia Pharma Basic Information, TKI for Chronic Myeloid Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 124. Eugia Pharma TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
Table 125. Eugia Pharma TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 126. Eugia Pharma Main Business
Table 127. Eugia Pharma Latest Developments
Table 128. Hetero Basic Information, TKI for Chronic Myeloid Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 129. Hetero TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
Table 130. Hetero TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 131. Hetero Main Business
Table 132. Hetero Latest Developments
Table 133. Sawai Pharmaceutical Basic Information, TKI for Chronic Myeloid Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 134. Sawai Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
Table 135. Sawai Pharmaceutical TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 136. Sawai Pharmaceutical Main Business
Table 137. Sawai Pharmaceutical Latest Developments
Table 138. Lupin Basic Information, TKI for Chronic Myeloid Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 139. Lupin TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
Table 140. Lupin TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 141. Lupin Main Business
Table 142. Lupin Latest Developments
Table 143. Apotex Basic Information, TKI for Chronic Myeloid Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 144. Apotex TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
Table 145. Apotex TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 146. Apotex Main Business
Table 147. Apotex Latest Developments
Table 148. Chia Tai Tianqing Pharmaceutical Basic Information, TKI for Chronic Myeloid Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 149. Chia Tai Tianqing Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
Table 150. Chia Tai Tianqing Pharmaceutical TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 151. Chia Tai Tianqing Pharmaceutical Main Business
Table 152. Chia Tai Tianqing Pharmaceutical Latest Developments
Table 153. Qilu Pharmaceutical Basic Information, TKI for Chronic Myeloid Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 154. Qilu Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
Table 155. Qilu Pharmaceutical TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 156. Qilu Pharmaceutical Main Business
Table 157. Qilu Pharmaceutical Latest Developments
Table 158. CSPC Ouyi Pharmaceutical Basic Information, TKI for Chronic Myeloid Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 159. CSPC Ouyi Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
Table 160. CSPC Ouyi Pharmaceutical TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 161. CSPC Ouyi Pharmaceutical Main Business
Table 162. CSPC Ouyi Pharmaceutical Latest Developments
Table 163. Suzhou Thery Pharmaceutical Basic Information, TKI for Chronic Myeloid Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 164. Suzhou Thery Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
Table 165. Suzhou Thery Pharmaceutical TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 166. Suzhou Thery Pharmaceutical Main Business
Table 167. Suzhou Thery Pharmaceutical Latest Developments
Table 168. Lunan Pharmaceutical Basic Information, TKI for Chronic Myeloid Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 169. Lunan Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolios and Specifications
Table 170. Lunan Pharmaceutical TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 171. Lunan Pharmaceutical Main Business
Table 172. Lunan Pharmaceutical Latest Developments
LIST OF FIGURES
Figure 1. Picture of TKI for Chronic Myeloid Leukemia
Figure 2. TKI for Chronic Myeloid Leukemia Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global TKI for Chronic Myeloid Leukemia Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global TKI for Chronic Myeloid Leukemia Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. TKI for Chronic Myeloid Leukemia Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. TKI for Chronic Myeloid Leukemia Sales Market Share by Country/Region (2025)
Figure 10. TKI for Chronic Myeloid Leukemia Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Imatinib
Figure 12. Product Picture of Nilotinib
Figure 13. Product Picture of Dasatinib
Figure 14. Product Picture of Bosutinib
Figure 15. Product Picture of Flumatinib
Figure 16. Product Picture of Ponatinib
Figure 17. Product Picture of Asciminib
Figure 18. Product Picture of Other
Figure 19. Global TKI for Chronic Myeloid Leukemia Sales Market Share by Type in 2026
Figure 20. Global TKI for Chronic Myeloid Leukemia Revenue Market Share by Type (2021-2026)
Figure 21. TKI for Chronic Myeloid Leukemia Consumed in Hospitals and clinics
Figure 22. Global TKI for Chronic Myeloid Leukemia Market: Hospitals and clinics (2021-2026) & (K Units)
Figure 23. TKI for Chronic Myeloid Leukemia Consumed in Pharmacies
Figure 24. Global TKI for Chronic Myeloid Leukemia Market: Pharmacies (2021-2026) & (K Units)
Figure 25. TKI for Chronic Myeloid Leukemia Consumed in Others
Figure 26. Global TKI for Chronic Myeloid Leukemia Market: Others (2021-2026) & (K Units)
Figure 27. Global TKI for Chronic Myeloid Leukemia Sale Market Share by Application (2025)
Figure 28. Global TKI for Chronic Myeloid Leukemia Revenue Market Share by Application in 2026
Figure 29. TKI for Chronic Myeloid Leukemia Sales by Company in 2026 (K Units)
Figure 30. Global TKI for Chronic Myeloid Leukemia Sales Market Share by Company in 2026
Figure 31. TKI for Chronic Myeloid Leukemia Revenue by Company in 2026 ($ millions)
Figure 32. Global TKI for Chronic Myeloid Leukemia Revenue Market Share by Company in 2026
Figure 33. Global TKI for Chronic Myeloid Leukemia Sales Market Share by Geographic Region (2021-2026)
Figure 34. Global TKI for Chronic Myeloid Leukemia Revenue Market Share by Geographic Region in 2026
Figure 35. Americas TKI for Chronic Myeloid Leukemia Sales 2021-2026 (K Units)
Figure 36. Americas TKI for Chronic Myeloid Leukemia Revenue 2021-2026 ($ millions)
Figure 37. APAC TKI for Chronic Myeloid Leukemia Sales 2021-2026 (K Units)
Figure 38. APAC TKI for Chronic Myeloid Leukemia Revenue 2021-2026 ($ millions)
Figure 39. Europe TKI for Chronic Myeloid Leukemia Sales 2021-2026 (K Units)
Figure 40. Europe TKI for Chronic Myeloid Leukemia Revenue 2021-2026 ($ millions)
Figure 41. Middle East & Africa TKI for Chronic Myeloid Leukemia Sales 2021-2026 (K Units)
Figure 42. Middle East & Africa TKI for Chronic Myeloid Leukemia Revenue 2021-2026 ($ millions)
Figure 43. Americas TKI for Chronic Myeloid Leukemia Sales Market Share by Country in 2026
Figure 44. Americas TKI for Chronic Myeloid Leukemia Revenue Market Share by Country (2021-2026)
Figure 45. Americas TKI for Chronic Myeloid Leukemia Sales Market Share by Type (2021-2026)
Figure 46. Americas TKI for Chronic Myeloid Leukemia Sales Market Share by Application (2021-2026)
Figure 47. United States TKI for Chronic Myeloid Leukemia Revenue Growth 2021-2026 ($ millions)
Figure 48. Canada TKI for Chronic Myeloid Leukemia Revenue Growth 2021-2026 ($ millions)
Figure 49. Mexico TKI for Chronic Myeloid Leukemia Revenue Growth 2021-2026 ($ millions)
Figure 50. Brazil TKI for Chronic Myeloid Leukemia Revenue Growth 2021-2026 ($ millions)
Figure 51. APAC TKI for Chronic Myeloid Leukemia Sales Market Share by Region in 2026
Figure 52. APAC TKI for Chronic Myeloid Leukemia Revenue Market Share by Region (2021-2026)
Figure 53. APAC TKI for Chronic Myeloid Leukemia Sales Market Share by Type (2021-2026)
Figure 54. APAC TKI for Chronic Myeloid Leukemia Sales Market Share by Application (2021-2026)
Figure 55. China TKI for Chronic Myeloid Leukemia Revenue Growth 2021-2026 ($ millions)
Figure 56. Japan TKI for Chronic Myeloid Leukemia Revenue Growth 2021-2026 ($ millions)
Figure 57. South Korea TKI for Chronic Myeloid Leukemia Revenue Growth 2021-2026 ($ millions)
Figure 58. Southeast Asia TKI for Chronic Myeloid Leukemia Revenue Growth 2021-2026 ($ millions)
Figure 59. India TKI for Chronic Myeloid Leukemia Revenue Growth 2021-2026 ($ millions)
Figure 60. Australia TKI for Chronic Myeloid Leukemia Revenue Growth 2021-2026 ($ millions)
Figure 61. China Taiwan TKI for Chronic Myeloid Leukemia Revenue Growth 2021-2026 ($ millions)
Figure 62. Europe TKI for Chronic Myeloid Leukemia Sales Market Share by Country in 2026
Figure 63. Europe TKI for Chronic Myeloid Leukemia Revenue Market Share by Country (2021-2026)
Figure 64. Europe TKI for Chronic Myeloid Leukemia Sales Market Share by Type (2021-2026)
Figure 65. Europe TKI for Chronic Myeloid Leukemia Sales Market Share by Application (2021-2026)
Figure 66. Germany TKI for Chronic Myeloid Leukemia Revenue Growth 2021-2026 ($ millions)
Figure 67. France TKI for Chronic Myeloid Leukemia Revenue Growth 2021-2026 ($ millions)
Figure 68. UK TKI for Chronic Myeloid Leukemia Revenue Growth 2021-2026 ($ millions)
Figure 69. Italy TKI for Chronic Myeloid Leukemia Revenue Growth 2021-2026 ($ millions)
Figure 70. Russia TKI for Chronic Myeloid Leukemia Revenue Growth 2021-2026 ($ millions)
Figure 71. Middle East & Africa TKI for Chronic Myeloid Leukemia Sales Market Share by Country (2021-2026)
Figure 72. Middle East & Africa TKI for Chronic Myeloid Leukemia Sales Market Share by Type (2021-2026)
Figure 73. Middle East & Africa TKI for Chronic Myeloid Leukemia Sales Market Share by Application (2021-2026)
Figure 74. Egypt TKI for Chronic Myeloid Leukemia Revenue Growth 2021-2026 ($ millions)
Figure 75. South Africa TKI for Chronic Myeloid Leukemia Revenue Growth 2021-2026 ($ millions)
Figure 76. Israel TKI for Chronic Myeloid Leukemia Revenue Growth 2021-2026 ($ millions)
Figure 77. Turkey TKI for Chronic Myeloid Leukemia Revenue Growth 2021-2026 ($ millions)
Figure 78. GCC Countries TKI for Chronic Myeloid Leukemia Revenue Growth 2021-2026 ($ millions)
Figure 79. Manufacturing Cost Structure Analysis of TKI for Chronic Myeloid Leukemia in 2026
Figure 80. Manufacturing Process Analysis of TKI for Chronic Myeloid Leukemia
Figure 81. Industry Chain Structure of TKI for Chronic Myeloid Leukemia
Figure 82. Channels of Distribution
Figure 83. Global TKI for Chronic Myeloid Leukemia Sales Market Forecast by Region (2027-2032)
Figure 84. Global TKI for Chronic Myeloid Leukemia Revenue Market Share Forecast by Region (2027-2032)
Figure 85. Global TKI for Chronic Myeloid Leukemia Sales Market Share Forecast by Type (2027-2032)
Figure 86. Global TKI for Chronic Myeloid Leukemia Revenue Market Share Forecast by Type (2027-2032)
Figure 87. Global TKI for Chronic Myeloid Leukemia Sales Market Share Forecast by Application (2027-2032)
Figure 88. Global TKI for Chronic Myeloid Leukemia Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of TKI for Chronic Myeloid Leukemia
Figure 2. TKI for Chronic Myeloid Leukemia Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global TKI for Chronic Myeloid Leukemia Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global TKI for Chronic Myeloid Leukemia Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. TKI for Chronic Myeloid Leukemia Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. TKI for Chronic Myeloid Leukemia Sales Market Share by Country/Region (2025)
Figure 10. TKI for Chronic Myeloid Leukemia Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Imatinib
Figure 12. Product Picture of Nilotinib
Figure 13. Product Picture of Dasatinib
Figure 14. Product Picture of Bosutinib
Figure 15. Product Picture of Flumatinib
Figure 16. Product Picture of Ponatinib
Figure 17. Product Picture of Asciminib
Figure 18. Product Picture of Other
Figure 19. Global TKI for Chronic Myeloid Leukemia Sales Market Share by Type in 2026
Figure 20. Global TKI for Chronic Myeloid Leukemia Revenue Market Share by Type (2021-2026)
Figure 21. TKI for Chronic Myeloid Leukemia Consumed in Hospitals and clinics
Figure 22. Global TKI for Chronic Myeloid Leukemia Market: Hospitals and clinics (2021-2026) & (K Units)
Figure 23. TKI for Chronic Myeloid Leukemia Consumed in Pharmacies
Figure 24. Global TKI for Chronic Myeloid Leukemia Market: Pharmacies (2021-2026) & (K Units)
Figure 25. TKI for Chronic Myeloid Leukemia Consumed in Others
Figure 26. Global TKI for Chronic Myeloid Leukemia Market: Others (2021-2026) & (K Units)
Figure 27. Global TKI for Chronic Myeloid Leukemia Sale Market Share by Application (2025)
Figure 28. Global TKI for Chronic Myeloid Leukemia Revenue Market Share by Application in 2026
Figure 29. TKI for Chronic Myeloid Leukemia Sales by Company in 2026 (K Units)
Figure 30. Global TKI for Chronic Myeloid Leukemia Sales Market Share by Company in 2026
Figure 31. TKI for Chronic Myeloid Leukemia Revenue by Company in 2026 ($ millions)
Figure 32. Global TKI for Chronic Myeloid Leukemia Revenue Market Share by Company in 2026
Figure 33. Global TKI for Chronic Myeloid Leukemia Sales Market Share by Geographic Region (2021-2026)
Figure 34. Global TKI for Chronic Myeloid Leukemia Revenue Market Share by Geographic Region in 2026
Figure 35. Americas TKI for Chronic Myeloid Leukemia Sales 2021-2026 (K Units)
Figure 36. Americas TKI for Chronic Myeloid Leukemia Revenue 2021-2026 ($ millions)
Figure 37. APAC TKI for Chronic Myeloid Leukemia Sales 2021-2026 (K Units)
Figure 38. APAC TKI for Chronic Myeloid Leukemia Revenue 2021-2026 ($ millions)
Figure 39. Europe TKI for Chronic Myeloid Leukemia Sales 2021-2026 (K Units)
Figure 40. Europe TKI for Chronic Myeloid Leukemia Revenue 2021-2026 ($ millions)
Figure 41. Middle East & Africa TKI for Chronic Myeloid Leukemia Sales 2021-2026 (K Units)
Figure 42. Middle East & Africa TKI for Chronic Myeloid Leukemia Revenue 2021-2026 ($ millions)
Figure 43. Americas TKI for Chronic Myeloid Leukemia Sales Market Share by Country in 2026
Figure 44. Americas TKI for Chronic Myeloid Leukemia Revenue Market Share by Country (2021-2026)
Figure 45. Americas TKI for Chronic Myeloid Leukemia Sales Market Share by Type (2021-2026)
Figure 46. Americas TKI for Chronic Myeloid Leukemia Sales Market Share by Application (2021-2026)
Figure 47. United States TKI for Chronic Myeloid Leukemia Revenue Growth 2021-2026 ($ millions)
Figure 48. Canada TKI for Chronic Myeloid Leukemia Revenue Growth 2021-2026 ($ millions)
Figure 49. Mexico TKI for Chronic Myeloid Leukemia Revenue Growth 2021-2026 ($ millions)
Figure 50. Brazil TKI for Chronic Myeloid Leukemia Revenue Growth 2021-2026 ($ millions)
Figure 51. APAC TKI for Chronic Myeloid Leukemia Sales Market Share by Region in 2026
Figure 52. APAC TKI for Chronic Myeloid Leukemia Revenue Market Share by Region (2021-2026)
Figure 53. APAC TKI for Chronic Myeloid Leukemia Sales Market Share by Type (2021-2026)
Figure 54. APAC TKI for Chronic Myeloid Leukemia Sales Market Share by Application (2021-2026)
Figure 55. China TKI for Chronic Myeloid Leukemia Revenue Growth 2021-2026 ($ millions)
Figure 56. Japan TKI for Chronic Myeloid Leukemia Revenue Growth 2021-2026 ($ millions)
Figure 57. South Korea TKI for Chronic Myeloid Leukemia Revenue Growth 2021-2026 ($ millions)
Figure 58. Southeast Asia TKI for Chronic Myeloid Leukemia Revenue Growth 2021-2026 ($ millions)
Figure 59. India TKI for Chronic Myeloid Leukemia Revenue Growth 2021-2026 ($ millions)
Figure 60. Australia TKI for Chronic Myeloid Leukemia Revenue Growth 2021-2026 ($ millions)
Figure 61. China Taiwan TKI for Chronic Myeloid Leukemia Revenue Growth 2021-2026 ($ millions)
Figure 62. Europe TKI for Chronic Myeloid Leukemia Sales Market Share by Country in 2026
Figure 63. Europe TKI for Chronic Myeloid Leukemia Revenue Market Share by Country (2021-2026)
Figure 64. Europe TKI for Chronic Myeloid Leukemia Sales Market Share by Type (2021-2026)
Figure 65. Europe TKI for Chronic Myeloid Leukemia Sales Market Share by Application (2021-2026)
Figure 66. Germany TKI for Chronic Myeloid Leukemia Revenue Growth 2021-2026 ($ millions)
Figure 67. France TKI for Chronic Myeloid Leukemia Revenue Growth 2021-2026 ($ millions)
Figure 68. UK TKI for Chronic Myeloid Leukemia Revenue Growth 2021-2026 ($ millions)
Figure 69. Italy TKI for Chronic Myeloid Leukemia Revenue Growth 2021-2026 ($ millions)
Figure 70. Russia TKI for Chronic Myeloid Leukemia Revenue Growth 2021-2026 ($ millions)
Figure 71. Middle East & Africa TKI for Chronic Myeloid Leukemia Sales Market Share by Country (2021-2026)
Figure 72. Middle East & Africa TKI for Chronic Myeloid Leukemia Sales Market Share by Type (2021-2026)
Figure 73. Middle East & Africa TKI for Chronic Myeloid Leukemia Sales Market Share by Application (2021-2026)
Figure 74. Egypt TKI for Chronic Myeloid Leukemia Revenue Growth 2021-2026 ($ millions)
Figure 75. South Africa TKI for Chronic Myeloid Leukemia Revenue Growth 2021-2026 ($ millions)
Figure 76. Israel TKI for Chronic Myeloid Leukemia Revenue Growth 2021-2026 ($ millions)
Figure 77. Turkey TKI for Chronic Myeloid Leukemia Revenue Growth 2021-2026 ($ millions)
Figure 78. GCC Countries TKI for Chronic Myeloid Leukemia Revenue Growth 2021-2026 ($ millions)
Figure 79. Manufacturing Cost Structure Analysis of TKI for Chronic Myeloid Leukemia in 2026
Figure 80. Manufacturing Process Analysis of TKI for Chronic Myeloid Leukemia
Figure 81. Industry Chain Structure of TKI for Chronic Myeloid Leukemia
Figure 82. Channels of Distribution
Figure 83. Global TKI for Chronic Myeloid Leukemia Sales Market Forecast by Region (2027-2032)
Figure 84. Global TKI for Chronic Myeloid Leukemia Revenue Market Share Forecast by Region (2027-2032)
Figure 85. Global TKI for Chronic Myeloid Leukemia Sales Market Share Forecast by Type (2027-2032)
Figure 86. Global TKI for Chronic Myeloid Leukemia Revenue Market Share Forecast by Type (2027-2032)
Figure 87. Global TKI for Chronic Myeloid Leukemia Sales Market Share Forecast by Application (2027-2032)
Figure 88. Global TKI for Chronic Myeloid Leukemia Revenue Market Share Forecast by Application (2027-2032)
